Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference

Rhea-AI Summary

Harpoon Therapeutics, a clinical-stage immuno-oncology company, announced its participation in the Canaccord Horizons in Oncology Conference on April 20, 2023. Julie Eastland, President and CEO, and Luke Walker, M.D., Chief Medical Officer, will join a panel discussion titled “T-Cell Engagers Coming of Age”, scheduled from 11:00-11:45 a.m. ET.

Harpoon specializes in developing T cell engagers using its proprietary TriTAC® platform, targeting solid tumors and hematologic malignancies. The company also employs the ProTriTAC™ and extended release TriTAC-XR platforms to enhance treatment efficacy and manage side effects. For more information, visit www.harpoontx.com.

SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that Julie Eastland, President and Chief Executive Officer, and Luke Walker, M.D., Chief Medical Officer, will participate in a panel and one-on-one meetings with institutional investors at the virtual Canaccord Horizons in Oncology Conference on April 20, 2023. The panel titled “T-Cell Engagers Coming of Age” will take place from 11:00-11:45 a.m. ET.

About Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.

Contacts:

ICR Westwicke:
Robert H. Uhl
Managing Director
858-356-5932
robert.uhl@westwicke.com

Media:
uncapped Communications
303-588-0599
kerry.walton@uncappedcommunications.com

FAQ

What is Harpoon Therapeutics announcing on April 20, 2023?

Harpoon Therapeutics is announcing its participation in the Canaccord Horizons in Oncology Conference, where its executives will be involved in a panel discussion.

Who will represent Harpoon Therapeutics at the Canaccord Conference?

Julie Eastland, President and CEO, and Luke Walker, M.D., Chief Medical Officer, will represent Harpoon Therapeutics.

What is the topic of Harpoon's panel at the conference?

The topic of the panel is “T-Cell Engagers Coming of Age”.

What time is Harpoon's panel discussion scheduled?

Harpoon's panel discussion is scheduled from 11:00-11:45 a.m. ET on April 20, 2023.

What technologies does Harpoon Therapeutics develop?

Harpoon develops T cell engagers using its TriTAC®, ProTriTAC™, and extended release TriTAC-XR platforms.